Zepbound for Obstructive Sleep Apnea

Who the indication covers

The approval is specific to adults with obesity and diagnosed moderate-to-severe obstructive sleep apnea. It does not mean that tirzepatide is appropriate for every person who snores or has mild, untested symptoms.

How it fits with PAP

One pivotal trial included patients using positive airway pressure and another included patients unable or unwilling to use it. Zepbound does not automatically replace PAP. Treatment decisions should consider apnea severity, oxygen effects, symptoms, cardiovascular risk, anatomy, PAP response and preference.

Read the FDA approval announcement.

Medication safety

Zepbound contains tirzepatide. Review the current label, contraindications, boxed warning, gastrointestinal effects, pancreatitis and gallbladder concerns, dehydration-related kidney risk, diabetes medications, pregnancy and planned anesthesia. Do not combine it with another tirzepatide product or GLP-1 receptor agonist.

How W8MD can help

W8MD reviews symptoms, sleep schedule, medical conditions, medications, prior testing and treatment goals, then recommends the appropriate evaluation or follow-up. Sleep and weight-management services can be coordinated when clinically relevant.

Sleep Medicine hub · Sleep apnea evaluation · Home sleep study · PAP support · Costs and insurance · Sleep apnea encyclopedia

Safety notice: General education only, not diagnosis or medical advice. Evaluation and testing determine the appropriate plan. Availability, coverage, costs and results vary. Do not drive when dangerously sleepy. Call 911 for trouble breathing, chest pain, stroke symptoms or another emergency.

Content reviewed for general accuracy by W8MD clinical leadership. Last reviewed September 2026.